Planning to attend #AAPS next month? Connect with our team to learn more about our integrated offerings in #drugproduct development, manufacturing, and #clinical testing. Schedule a meeting with our experts today: https://bit.ly/45W8ZdP
Quotient Sciences
Pharmaceutical Manufacturing
Nottingham, Nottinghamshire 24,447 followers
Molecule to cure. Fast.
About us
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast. We employ over 1,300+ staff and operate from state-of-the-art manufacturing and clinical facilities in the US and UK. Our people make Quotient Sciences a special place to work. We are a dedicated team passionate about innovating and transforming drug development to help our customers develop new medicines for patients in need. We recruit people that are committed to making a difference, who excel at customer service and are always willing to go the extra mile. Teamwork is integral to our culture and success — helping, supporting and mentoring run through our DNA. Expect to join an empowering and innovative culture, where we encourage continuous improvement and offer opportunities to learn and develop every day.
- Website
-
https://bit.ly/3u9sI6l
External link for Quotient Sciences
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Nottingham, Nottinghamshire
- Type
- Privately Held
- Specialties
- CDMO, Formulation Development, Phase I & II Clinical Trial Manufacturing, Translational Pharmaceutics, High Potency Handling, Real-time Adaptive Manufacturing, Commercial Manufacturing, Solubility Enhancement, Modified Release, Pediatric Formulation Development, CRO, First-in-Human, Clinical Pharmacology, Relative Bioavailability, Pharmacokinetics, Drug-Drug Interaction, Human ADME / 14C, Data Sciences, Modelling & Simulation, Drug Substance, Scintigraphy, Bioanalysis, Isotope Labelling, Clinical Trial Supplies, Bioequivalence, Healthy Volunteer Studies, Proof-of-Concept, Drug Development, and Dosage Form Development
Products
Locations
Employees at Quotient Sciences
Updates
-
The transition from preclinical to clinical testing is a pivotal but challenging moment in drug development. Partnering with an experienced first-in-human specialist such as #QuotientSciences is the key to navigating this critical phase with confidence. Through our work with small molecules and biologics, we provide the expertise, infrastructure, and agility needed to move your novel therapy forward, faster. Learn more today: https://bit.ly/3KX2X4r
-
Our 2024 ESG report highlights the progress we’ve made—from deepening our climate data reporting and expanding DEI training, to launching community outreach and sustainability initiatives. Download now: https://bit.ly/4gQCjq9
-
Not every drug product fits a large-scale manufacturing model: We support niche and orphan drug programs with specialized expertise and small-batch flexibility that never compromises quality. Learn more about our services: https://bit.ly/41WfU4A
-
Latest news: Quotient Sciences and Biorasi announced today a strategic partnership to deliver fully integrated early phase clinical trial solutions. Combining Quotient Sciences' expertise in early clinical development with Biorasi’s global patient recruitment capabilities, this collaboration addresses a growing demand for hybrid clinical trial designs that include both healthy volunteer studies and patient cohorts. Read the full announcement: https://bit.ly/4hiAaUk
-
-
Highly potent active pharmaceutical ingredients (HPAPIs) are becoming increasingly common in #drugdevelopment pipelines, however these often present additional #CMC challenges. Learn how we help overcome these challenges to advance drug product formulation and manufacturing: https://bit.ly/4nJKA1F
-
Today, on World Mental Health Day, we’re proud to mark the end of a week where our teams came together to focus on our mental well-being. From an expert webinar led by Kerry Quigley to yoga sessions and a wrap-up filled with kindness, we’ve created space to talk, reflect and support each other. It’s been a week of open conversations, practical tools and shared moments that remind us—it’s okay to ask for help. Because at Quotient Sciences, we don’t just care about what you deliver — we care about how you’re really doing.
-
-
Don't miss our seminar happening in Houston: Led by Robert Cornog, Senior Director of Product Development, learn how we've helped clients with accelerated regulatory designations bring innovative treatments to market swiftly while mitigating CMC risks along the way. Register: https://bit.ly/42zjXnw
This content isn’t available here
Access this content and more in the LinkedIn app
-
Dr. Andy Lewis, Chief Scientific Officer, recently contributed to PharmaSource's article focused on strong sponsor and #CDMO partnerships. Read his perspective on how Quotient Sciences have helped clients address their clinical testing and drug development, manufacturing and scale-up challenges: https://bit.ly/4pZM5dv
-
-
Small-batch drug product manufacturing that doesn’t compromise quality. Learn more about the capabilities that we offer from our US-based drug product facilities near Philadelphia, PA: https://bit.ly/4cU6s4z